NCT00542217已完成1 期
Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Safety, Pharmacodynamics, and Pharmacokinetics Study of Intravenous Imprime PGG™ Injection in Healthy Adult Subjects
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 主要终点
- Evaluate the safety and tolerability of a single intravenous dose of Imprime PGG™ Injection (Imprime PGG) versus placebo when administered to healthy adult subjects by assessing the frequency, type, and severity of adverse events.
研究概览
简要总结
The purpose of this trial is to the assess the safety, pharmacodynamics, and pharmacokinetics of escalating doses of Imprime PGG™ Injection in healthy volunteers.
详细描述
The primary objective of this study is to evaluate the safety and tolerability of a single intravenous dose of Imprime PGG versus placebo when administered to healthy adult subjects by assessing the frequency, type, and severity of treatment emergent adverse events.
The secondary objectives are:
- to determine the pharmacodynamics of a single intravenous dose of Imprime PGG when administered to healthy adult subjects by assessing the number of subjects who experience a 15% or more increase from baseline in the percentage of neutrophils with primed CR3; and
- to derive the pharmacokinetic profile of a single intravenous dose of Imprime PGG when administered to healthy adult subjects by assessing the plasma concentration of Imprime PGG versus time.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Be aged 18 to 45 years, inclusive
- •Have a body weight of 45 to 125 kg, inclusive, and a body mass index less than or equal to 30 kg/m2
- •If female, be nonpregnant and nonnursing, and if premenopausal, have a negative urine pregnancy test confirmed prior to enrollment and practicing at least two methods of birth control
- •Be healthy as determined by the investigator on the basis of medical history, the physical examination, electrocardiogram, and clinical laboratory test results
- •Have the ability to understand the requirements of the study, have provided written informed consent, and agree to abide by the study restrictions and to return for the required assessments
- •Have provided written authorization for use and disclosure of protected health information
排除标准
- •Have a known hypersensitivity to baker's yeast
- •Have a history of tobacco use within 3 months of the Screening Period
- •Be a known or suspected abuser of alcohol or other drugs of abuse
- •Have an active yeast infection
- •Have a positive hepatitis B, hepatitis C, or human immunodeficiency virus test during the Screening Period
- •Except as otherwise indicated, have taken any prescription medication within 14 days of study drug administration on Day 0 or over-the-counter medication, herbal preparation, or vitamins within 1 week of study drug administration on Day 0 (The following medications are exempted from this criterion: acetaminophen [maximum 3 g/day], female hormone replacement therapy, and oral contraceptives.)
- •Have participated in an investigational drug study within 30 days or five half-lives (whichever is longer) of the Screening Period
- •Have donated or lost more than a unit of blood within 30 days of the Screening Period
- •Have any clinical condition that, in the opinion of the principal investigator, warrants exclusion from the study for either a scientific, procedural, or safety perspective
结局指标
主要结局
Evaluate the safety and tolerability of a single intravenous dose of Imprime PGG™ Injection (Imprime PGG) versus placebo when administered to healthy adult subjects by assessing the frequency, type, and severity of adverse events.
时间窗: Prospective
次要结局
- -To determine the pharmacodynamics of a single intravenous dose of Imprime PGG by assessing the number of subjects who experience a 15% or more increase from baseline in the percentage of neutrophils with primed complement receptor 3 (CR3)(Prospective)
- To derive the pharmacokinetic profile of a single intravenous dose of Imprime PGG, when administered to healthy adult subjects, by assessing the plasma concentration of Imprime PGG versus time.(Prospective)
研究者
相似试验
已完成
1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HMS5552 in Patients With Type 2 DiabetesType 2 Diabetes MellitusNCT02077452Hua Medicine Limited53
终止
4 期
A Study to Evaluate the Use of Extended Release Alprazolam in the Treatment of Adolescents With Panic DisorderPanic DisorderNCT00635531Pfizer's Upjohn has merged with Mylan to form Viatris Inc.16
已完成
1 期
IPI-145 Single Ascending, Multiple Ascending, Food Effect and Drug-Drug-Interaction StudyHealthy VolunteersNCT01549106SecuraBio106
招募中
1 期
A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RS-C1001 Tablets in Chinese Healthy SubjectsDyslipidemiaNCT0666942972
已完成
1 期
BN201 SAD MAD Study in Healthy SubjectsOptic NeuritisNeuritis, With Demyelination OpticNCT03630497Accure Therapeutics48